Literature DB >> 9044168

A comparison of a Bayesian population method with two methods as implemented in commercially available software.

J E Bennett1, J C Wakefield.   

Abstract

In this paper we describe and discuss three specific estimation procedures that are available within commercially available population software packages. The first version of NONMEM (l) was released in 1979 and later versions are the standard analysis tools in both industry and academia. Recently, two commercially available pieces of software have become available. PPHARM was released during 1994 and POPKAN was released in 1995. We provide descriptions and critique the FOCE method within NONMEM, the two-step algorithm within PPHARM and the Markov chain Monte Carlo method that is utilized by POPKAN. We use simulated data generated from a monoexponential model to evaluate the parameter estimation capabilities of these methods within the three software tools. In particular we investigate the effect on parameter estimation of increasing both interindividual and intraindividual variability.

Mesh:

Year:  1996        PMID: 9044168     DOI: 10.1007/bf02353520

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  19 in total

1.  A population approach to initial dose selection.

Authors:  J Wakefield; S Walker
Journal:  Stat Med       Date:  1997-05-30       Impact factor: 2.373

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.

Authors:  F Mentré; R Gomeni
Journal:  J Biopharm Stat       Date:  1995-07       Impact factor: 1.051

4.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

5.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography.

Authors:  L Yuh; S Beal; M Davidian; F Harrison; A Hester; K Kowalski; E Vonesh; R Wolfinger
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

Review 6.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

7.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

8.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

9.  Bayesian estimation of p-aminohippurate clearance by a limited sampling strategy.

Authors:  J M Kinowski; M Rodier; F Bressolle; D Fabre; V Augey; J L Richard; M Galtier; R Gomen
Journal:  J Pharm Sci       Date:  1995-03       Impact factor: 3.534

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  19 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

3.  The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical data.

Authors:  Maria C Kjellsson; Siv Jönsson; Mats O Karlsson
Journal:  AAPS J       Date:  2004-08-11       Impact factor: 4.009

4.  Improving pharmacokinetic-pharmacodynamic models of muscle relaxants using potentiation modelling.

Authors:  Douglas J Eleveld; Johannes H Proost; Ann De Haes; J Mark K H Wierda
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

5.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.

Authors:  Andrew Hooker; Paolo Vicini
Journal:  AAPS J       Date:  2005-11-01       Impact factor: 4.009

6.  Parametric and nonparametric population methods.

Authors:  Johannes H Proost; Douglas J Eleveld
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.

Authors:  Johannes H Proost; Douglas J Eleveld
Journal:  Pharm Res       Date:  2006-11-07       Impact factor: 4.200

8.  Twitch potentiation influences the time course of twitch depression in muscle relaxant studies: a pharmacokinetic-pharmacodynamic explanation.

Authors:  Douglas J Eleveld; Johannes H Proost; J Mark K H Wierda
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

9.  Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation.

Authors:  V H M Deneer; L Lie-A-Huen; J H Kingma; J H Proost; S A Gossen; A Stuurman; G M M Uytdehaag; P H J M Dunselman; J R B J Brouwers
Journal:  Eur J Clin Pharmacol       Date:  2004-11-16       Impact factor: 2.953

10.  Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.

Authors:  Andrew C Hooker; Christine E Staatz; Mats O Karlsson
Journal:  Pharm Res       Date:  2007-07-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.